Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Prelude Therapeutics Inc. on June 16, 2023. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol PRLD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Three proposals were submitted to and adopted by the stockholders:
- Election of Directors: Krishna Vaddi, Ph.D., and Mardi C. Dier were elected as Class III Directors for three-year terms expiring in 2026.
- Ratification of Auditors: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Charter Amendment: An amendment to the Restated Certificate of Incorporation was approved to reflect new Delaware law provisions regarding officer exculpation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the terms of office for the newly elected directors, Krishna Vaddi and Mardi C. Dier.
- Confirm the appointment of Ernst & Young LLP as the auditor for the 2023 fiscal year.
- Review the specific language of the amendment to the Restated Certificate of Incorporation regarding officer exculpation.
- Check the total number of shares voted and the percentage of broker non-votes (986,106) for each proposal.